Does Adipotide help with fat loss?

What the studies show

No human efficacy or safety data exists in the literature. The registered phase 1 (prostate cancer, not obesity) has no published result.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

1. 1
   Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.Sci Transl Med, 2011Rhesus and other monkeys; preclinical; reversible kidney toxicity reported.
2. 2
   Searches of PubMed and ClinicalTrials.gov for adipotide in humans.LYO literature search, September 2026Seven PubMed results, none clinical; the registered phase 1 (prostate cancer) has no published result.

In context

Adipotide is a two-part synthetic peptide: a homing sequence that binds a protein on the blood vessels of white fat, joined to a fragment that triggers cell death. Cut off the blood supply and the fat tissue shrinks. In obese monkeys it produced rapid weight loss and better insulin sensitivity — and dose-dependent, reversible kidney damage. A human phase 1 trial in prostate cancer was registered in 2010 and no result was ever published. It is sold online as a fat-loss peptide on the strength of the monkey study. It is not approved anywhere and is prohibited in sport.

Adipotide is not approved; investigational (stalled). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Other outcomes for Adipotide

• DFat loss (obese primates)Preclinical only
• DKidney toxicity (primates)adversePreclinical only

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →